LIFETECH SCI (01302) plans to acquire approximately 96.46% equity of Beijing Huayi Shengjie Technology for about 1.873 billion yuan.

LIFETECH SCI (01302) announced on May 22, 2026, that the company intends to acquire approximately 96.46% equity of Beijing Huayi Shengjie Technology Co., Ltd. (Huayi) from the seller AUT-VII HK Holdings Limited. The transaction price is approximately 1.873 billion RMB. The price will be paid by the company through the issuance of convertible bonds to the seller. After the completion of the transaction, Huayi will become a non-wholly owned subsidiary of the company, and its financial performance will be consolidated into the group's financial statements. As a medical device company, Huayi is mainly engaged in the research and development, manufacturing, and sales of vascular interventional medical devices. Huayi's products are mainly used for the treatment of congenital heart defects and the prevention of cardioembolic stroke. Huayi launched one of the first domestically produced occluders for congenital heart disease in China in 2003, and introduced China's first patent foramen ovale (PFO) occluder product in 2009. Huayi is primarily engaged in the research and development, manufacturing, and sales of vascular interventional medical devices, and has competitive advantages in proprietary technology, market access, and research and development capabilities. The directors believe that the acquisition of Huayi is in line with the overall development strategy of the group and will bring long-term benefits to the company.